Abzena plc

Block Listing Update

Cambridge, UK, 06 July 2018- Abzena plc (AIM: ABZA, 'Abzena' or the 'Group') announces the following block listing update in respect of its block listing for the Group's 2013 Share Incentive Plan, in accordance with AIM Rule 29. An update in accordance with Schedule 6 of the AIM Rules for Companies is set out below. The Group has a total issued share capital of 214,220,399 ordinary shares of £0.002 each and holds no shares in Treasury. Each ordinary share carries one vote. The total number of voting rights in the Company is therefore 214,220,399.

BLOCK LISTING SIX MONTHLY RETURN

Name of applicant:

Abzena plc

Name of scheme:

Abzena plc 2013 Share Incentive Plan

Period of return:

From:

3 January 2018

To:

6 July 2018

Balance of unallotted securities under scheme(s) from previous return:

544,249

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Less: Number of securitiesissued/allotted under scheme(s) during period (see LR3.5.7G):

Nil

Equals: Balance under scheme(s) not yet issued/allotted at end of period

544,249

Number and class of securities originally admitted and the date of admission

1,779,000 ordinary shares of £0.002 each, admitted on 13 July 2015

Name of contact:

Julian Smith

Telephone number of contact:

+44 1223 903 498

-Ends-

Enquiries:

Abzena plc

John Burt, Chief Executive Officer

+44 1223 903498

Numis(Nominated Adviser and Broker)

Clare Terlouw / James Black / Paul Gillam

+44 20 7260 1000

N+1 Singer(Joint Broker)

Aubrey Powell / Liz Yong

+44 20 7496 3000

Instinctif Partners

Melanie Toyne Sewell / Rozi Morris / Alex Shaw

+44 20 7457 2020

abzena@instinctif.com

Notes to Editors

About Abzena

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'ABZENAInside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ABZENAInside products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

· Biology research studies, including immunogenicity assessment of candidate biopharmaceutical products and bioassay development;

· Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;

· Cell line development for the manufacture of recombinant proteins and antibodies;

· Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

· Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

· Proprietary site-specific conjugation technologies and novel payloads for ADC development;

· GMP manufacturing of ADC linkers, payloads & combined linker-payloads; and

· GMP analytical services for biopharmaceutical manufacturing projects.

For more information, please see www.abzena.com.

Attachments

  • Original document
  • Permalink

Disclaimer

Abzena plc published this content on 06 July 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 06 July 2018 15:13:01 UTC